Skip to main content

Newsoara Says Lead Drug Effective in Gastrointestinal Surgery Patients

Newsoara, a Shanghai in-licensing company, said its lead drug candidate completed a successful China Phase II trial in gastrointestinal surgery patients. LB1148 lowered the time to return of bowel function following elective bowel resection, though the company did not provide specific data. The candidate is an oral broad-spectrum serine protease inhibitor designed to neutralize digestive proteases released from the gut during surgery. Newsoara in-licensed greater China rights to LB1148 from Palisade Bio (NSDQ: PALI) of Carlsbad , CA . More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.